The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net loss | -67,274 | -92,574 | -129,666 | -59,179 |
| Change in fair value of related-party convertible note | -1,169 | 1,169 | -42,582 | 43,472 |
| Non-cash interest expense related to revenue interest liability | 9,310 | 10,019 | 13,266 | 10,289 |
| Stock-based compensation expense | 8,878 | 9,648 | 9,537 | 9,038 |
| Change in fair value of warrant liabilities | -14,905 | -3,889 | 448 | -9,733 |
| Depreciation and amortization | 3,951 | 3,880 | 3,829 | 4,138 |
| Change in fair value of derivative liabilities | -289 | -1,931 | -5,578 | 6,607 |
| Non-cash lease expense related to operating lease right-of-use assets-Nonrelated Party | 830 | 905 | 925 | - |
| Transaction costs allocated to warrant liabilities | 2,063 | 104 | - | 0 |
| Non-cash lease expense related to operating lease right-of-use assets-Related Party | 698 | 678 | 658 | - |
| Non-cash lease expense related to operating lease right-of-use assets | - | - | - | 1,615 |
| Non-cash interest items, net | 63 | 62 | 62 | -1,337 |
| Accretion of discounts on marketable debt securities | 978 | 11 | 52 | 24 |
| Impairment of intangible assets | - | - | - | 0 |
| Unrealized losses on equity securities | 1 | - | -1 | -112 |
| Impairment of fixed assets | - | - | - | 0 |
| Amortization of related-party notes discounts | 0 | 0 | 0 | 5,007 |
| Other | 35 | 211 | 242 | -37 |
| Accounts receivable | 9,890 | 5,097 | 14,669 | -1,815 |
| Inventories | 63 | -1,804 | 172 | 6,314 |
| Prepaid expenses and other current assets-Nonrelated Party | 5,578 | 3,939 | -114 | - |
| Prepaid expenses and other current assets | - | - | - | -1,333 |
| Prepaid expenses and other current assets-Related Party | -738 | 205 | -951 | - |
| Other assets | 324 | -1,227 | 84 | 1,034 |
| Accounts payable | -1,392 | -6,216 | 6,439 | -3,214 |
| Accrued expenses and other liabilities | 5,469 | 8,723 | -12,933 | -2,114 |
| Due to and due from related parties, net | 501 | -7 | 51 | 223 |
| Operating lease liabilities-Nonrelated Party | -912 | -992 | -916 | - |
| Operating lease liabilities | - | - | - | -1,537 |
| Operating lease liabilities-Related Party | -881 | -852 | -816 | - |
| Net cash used in operating activities | -68,907 | -79,746 | -85,905 | -85,144 |
| Purchases of marketable debt securities, available-for-sale | 180,586 | 15,061 | 100 | 6,089 |
| Proceeds from maturities of marketable debt securities, available-for-sale | 0 | 0 | 5,350 | 18,034 |
| Purchases of property, plant and equipment | 741 | 1,081 | 1,121 | 2,111 |
| Software development costs | 34 | - | - | - |
| Proceeds from sales of marketable debt securities | 0 | 0 | 0 | 0 |
| Acquisition of a business, net of transaction costs | 0 | - | - | 0 |
| Cash paid for other investments | 0 | - | - | 0 |
| Purchase of intangible assets | - | - | - | 0 |
| Investment in joint venture an equity method investment | - | - | - | 0 |
| Net cash used in investing activities | -181,361 | -16,142 | 4,129 | 9,834 |
| Proceeds from equity offerings, net of issuance costs-Private Placement And At The Market Offerings | 173,682 | 173,136 | - | 107,732 |
| Net share settlement for rsus vesting | 151 | 322 | 1,202 | 803 |
| Proceeds from exercises of stock options-Options Excluding Stock Purchase And Option Agreement | - | - | - | 715 |
| Proceeds from exercises of stock options-Exercise Of Stock Options | 0 | 0 | -495 | - |
| Principal payments of finance leases | 12 | 4 | 0 | 0 |
| Proceeds from issuance of related-party promissory notes net of issuance costs paid | - | - | - | 0 |
| Proceeds from the ripa, net of issuance costs | 0 | 0 | - | 0 |
| Issuance of common stock-Stock Purchase And Option Agreement | - | - | - | 0 |
| Proceeds from exercises of warrants | 0 | 0 | 0 | 0 |
| Payment for contingent consideration | - | - | - | 0 |
| Payment of revenue interest liability | - | - | -3 | - |
| Proceeds from exercises of stock options-Stock Purchase And Option Agreement | 0 | 0 | - | 0 |
| Net cash provided by financing activities | 173,519 | 172,810 | -982 | 106,929 |
| Effect of exchange rate changes on cash and cash equivalents, and restricted cash | -56 | 76 | -10 | -7 |
| Net change in cash and cash equivalents, and restricted cash | -76,805 | 76,998 | -82,768 | 31,612 |
| Cash and cash equivalents at beginning of period | 138,142 | 61,144 | 143,912 | 112,300 |
| Cash and cash equivalents at end of period | 61,337 | 138,142 | 61,144 | 143,912 |
ImmunityBio, Inc. (IBRX)
ImmunityBio, Inc. (IBRX)